Business In Brief
This article was originally published in The Tan Sheet
Executive Summary
Pfizer: Consumer Healthcare sales of $741 mil., up 14%, in the second quarter, were driven by the continued strong performance of Listerine mouthwash and uptake of Listerine PocketPaks in international markets. The rollout of FreshBurst Listerine line extensions and the weaker dollar also helped edge up revenues. Sales of PocketPaks in the U.S. slowed and the firm's Benadryl and Sudafed line were hurt by the presence of OTC Claritin on the market, Pfizer notes...